Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2026)

Aquestive Therapeutics' Non-Current Debt history runs 10 years deep, the most recent figure standing at $25.1 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 25.62% year-over-year to $25.1 million; the TTM figure through Mar 2026 stood at $25.1 million (down 25.62% YoY), while the FY2025 annual figure was $27.5 million, down 15.33% from the prior year.
• Non-Current Debt was $25.1 million for Q1 2026 at Aquestive Therapeutics, down from $27.5 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $47.7 million in Q1 2022 to a low of $17.5 million in Q2 2024.
• Historically, Non-Current Debt has averaged $30.4 million across 5 years, with a median of $29.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt sank 52.53% in 2023, then jumped 82.2% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $33.4 million in 2022, then dropped by 17.76% to $27.5 million in 2023, then increased by 18.15% to $32.5 million in 2024, then decreased by 15.33% to $27.5 million in 2025, then dropped by 8.79% to $25.1 million in 2026.
• The last three Non-Current Debt figures came in at $25.1 million (Q1 2026), $27.5 million (Q4 2025), and $29.9 million (Q3 2025), per Business Quant data.